[Edaily Reporter Park Jung-Soo ] Emergency medical device manufacturer CU MEDICAL SYSTEMS Inc.(115480)saw a significant improvement in its first-half performance, driven by expanded overseas sales and cost efficiency. CU MEDICAL SYSTEMS Inc. announced on the 18th that it recorded first-half revenue of 29.3 billion won and operating profit of 9.86 billion won on a standalone basis. These figures represent year-over-year increases of 55.4% and 181.4%, respectively. Profitability also improved significantly. The operating profit margin rose by approximately 15 percentage points, from 18.6% in the first half of last year to 33.7% this year. The company explained that this result reflects increased domestic and international sales, along with reductions in cost of goods sold and selling, general, and administrative expenses. In particular, the company noted that results are now fully materializing in overseas markets where it has long focused its efforts. CU MEDICAL SYSTEMS Inc. has developed automated external defibrillators (AEDs), secured relevant certifications in Europe and the United States, and established local sales networks. In the first half of this year, increased overseas sales—particularly in Europe—drove earnings growth. Net income reached 10.6 billion won, a 929.2% increase from the 1 billion won recorded in the same period last year. However, net income partially reflected non-operating gains and losses, such as valuation gains on financial assets held. On a consolidated basis, first-half revenue totaled 35.4 billion won, and operating profit reached 8.5 billion won. The company plans to continue its earnings growth trend in the second half, building on the momentum of expanding domestic and international sales. CU MEDICAL SYSTEMS Inc. official stated, “Our long-term investments in obtaining overseas certifications and establishing sales networks are now translating into results, particularly in Europe,” adding, “Combined with expanded domestic sales and cost-saving measures, our first-half performance improved significantly, and we plan to maintain this growth momentum in the second half.”
“At Kim & Chang, we collaborate organically with industry-specific practice groups during mergers and acquisitions (M&A), so we can always rely on the assistance of fellow experts who are well-versed …
Psomagen, Inc.(950200)announced on the 14th, through its 2026 interim financial statements, that it recorded an operating profit of $93,000 (140 million won) in the first half of the year, successfull…
DuChemBio Co.,LTD.(176750), a company specializing in radiopharmaceuticals, announced on the 18th that it recorded sales of 20.9 billion won and operating profit of 3.2 billion won in the first half o…